Journal ArticleDOI
Inhibition of osteolytic bone lesions by (3-amino-1-hydroxypropylidene)-1, 1-bisphosphonate (A.P.D.).
Reads0
Chats0
TLDR
Serum-calcium dropped to low normal values in all 14 patients, accompanied by a decrease in urine calcium and hydroxyproline excretion-rate, and results show that A.P.D. may inhibit tumour-induced osteolysis.About:
This article is published in The Lancet.The article was published on 1979-04-14. It has received 169 citations till now. The article focuses on the topics: Osteolysis & Bone disease.read more
Citations
More filters
Journal ArticleDOI
Efficacy of Pamidronate in Reducing Skeletal Events in Patients with Advanced Multiple Myeloma
James R. Berenson,Alan Lichtenstein,Lester Porter,Meletios A. Dimopoulos,Roldolfo Bordoni,Sebastian George,Allan Lipton,Alan Keller,O. F. Ballester,Michael J. Kovacs,Hilary A. Blacklock,Richard Bell,Joseph F. Simeone,Dirk J. Reitsma,Maika Heffernan,John J. Seaman,Robert Knight +16 more
TL;DR: Monthly infusions of pamidronate provide significant protection against skeletal complications and improve the quality of life of patients with stage III multiple myeloma.
Journal ArticleDOI
Bisphosphonates: The first 40 years
TL;DR: The discovery and development of the bisphosphonates (BPs) as a major class of drugs for the treatment of bone diseases has been a fascinating story, and a paradigm of a successful journey from 'bench to bedside'.
Journal ArticleDOI
Pamidronate Reduces Skeletal Morbidity in Women With Advanced Breast Cancer and Lytic Bone Lesions: A Randomized, Placebo-Controlled Trial
Richard L. Theriault,Allan Lipton,Gabriel N. Hortobagyi,Richard Leff,Stefan Glück,John F. Stewart,Sean Costello,Ian Kennedy,Joseph F. Simeone,John J. Seaman,Robert Knight,Kathleen Mellars,Maika Heffernan,Dirk J. Reitsma +13 more
TL;DR: In this paper, the authors evaluated whether pamidronate can reduce the frequency of skeletal morbidity in women with lytic bone metastases from breast cancer treated with hormone therapy.
Journal ArticleDOI
Bisphosphonates. Pharmacology and use in the treatment of tumour-induced hypercalcaemic and metastatic bone disease.
TL;DR: By inhibiting bone resorption, these compounds correct hypercalcaemia and hypercalciuria, reduce pain, the occurrence of fractures, as well as the development of new osteolytic lesions, and in consequence improve the quality of life.
Journal ArticleDOI
Quantitative morphometric evaluation of the inhibitory activity of new aminobisphosphonates on bone resorption in the rat.
TL;DR: AHBuBP and possibly AHHexBP appear to be interesting new bisphosphonates for future clinical use.
References
More filters
Journal ArticleDOI
A specific method for the analysis of hydroxyproline in tissues and urine.
Journal ArticleDOI
Evidence for the secretion of an osteoclast stimulating factor in myeloma.
TL;DR: It is suggested that osteolytic bone lesions and hypercalcemia in Myeloma are due to the secretion of a soluble factor by myeloma cells that in turn stimulates osteoclastic bone resorption in organ culture.
Journal ArticleDOI
Treatment for multiple myeloma. Combination chemotherapy with different melphalan dose regimens.
Raymond Alexanian,Arthur Haut,Asad U. Khan,Montague Lane,Eugene M. McKelvey,Philip J. Migliore,W. J. Stuckey,Henry E. Wilson +7 more
TL;DR: Results support the use of intermittent courses of concurrent chemotherapy with large doses of melphalan and prednisone in patients with multiple myeloma.
Journal ArticleDOI
Mechanisms of bone destruction in the development of skeletal metastases
TL;DR: Experiments indicate that two principal mechanisms are involved in the pathogenesis of bone metastases and the first is mediated by osteoclasts and the tumour secretes a diffusable osteoclast activating factor; the second functions when the residual trabeculae are surrounded by the tumours.
Journal ArticleDOI
Treatment of paget's disease with (3-amino-1-hydroxypropylidene)-1, 1-bisphosphonate (a.p.d.)
TL;DR: 18 patients with Paget's disease were treated orally with (3-amino-1-hydroxypropylidene)-1, 1-bisphosphonate (A.P.D.), and in most cases bone resorption became normal within a week of treatment, whereas the return to normal bone formation took 3-6 months; this difference produced a transient imbalance between Resorption and formation.